Nektar Therapeutics Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
Nektar Therapeutics (NKTR) had Operating Leases, Future Minimum Payments, Remainder of Fiscal Year of $1.30 million as of 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear · last filed 2017-11-08
- 2017-09-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $1.30M.
| Period end | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year |
|---|---|
| 2017-09-30 | $1.30M 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |